Jeffrey I Frank1, L Philip Schumm, Kristen Wroblewski, Douglas Chyatte, Axel J Rosengart, Christi Kordeck, Ronald A Thisted. 1. From the Departments of Neurology (J.I.F., C.K.), Health Studies (L.P.S., K.W., R.A.T.), Statistics (R.A.T.), Anesthesia and Critical Care (R.A.T.), The University of Chicago, IL; Department of Neurosurgery, Mayo Clinic College of Medicine, Rochester, MN (D.C.); and Department of Neurology, Weill Cornell Medical College, New York (A.J.R.).
Abstract
BACKGROUND AND PURPOSE:Hemicraniectomy and Durotomy Upon Deterioration From Infarction-Related Swelling Trial (HeADDFIRST) was a randomized pilot study to obtain information necessary to design a Phase III trial to evaluate the benefit of surgical decompression for brain swelling from large supratentorial cerebral hemispheric infarction. METHODS:All patients with stroke were screened for eligibility (age 18-75 years, National Institutes of Health Stroke Scale≥18 with Item 1a<2 [responsive to minor stimulation], and CT demonstrating unilateral, complete middle cerebral artery territory infarction by specific imaging criteria). All enrolled patients were treated using a standardized medical treatment protocol. Those with both≥4 mm of pineal shift and deterioration in level of arousal or ≥7.5 mm of anteroseptal shift within 96 hours of stroke onset were randomized to continued medical treatment only or medical treatment plus surgery. Death at 21 days was the primary outcome measure. RESULTS: Among 4909 screened patients, only 66 (1.3%) patients were eligible for HeADDFIRST. Forty patients were enrolled, and 26 patients developed the requisite brain swelling for randomization. All who failed to meet randomization criteria were alive at 21 days. Mortality at 21 and 180 days was 40% (4/10) in the medical treatment only and 21% (3/14) and 36% (5/14) in the medical treatment plus surgery arms, respectively. CONCLUSIONS: HeADDFIRST randomization criteria effectively distinguished low from high risk of death from large supratentorial cerebral hemispheric infarction. Lower mortality in the medical treatment only group than in other published trials suggests a possible benefit to standardizing medical management. These results can inform the interpretation of recently completed European trials concerning patient selection and medical management. CLINICAL TRIAL REGISTRATION: This trial was not registered because enrollment began before July 1, 2005.
RCT Entities:
BACKGROUND AND PURPOSE: Hemicraniectomy and Durotomy Upon Deterioration From Infarction-Related Swelling Trial (HeADDFIRST) was a randomized pilot study to obtain information necessary to design a Phase III trial to evaluate the benefit of surgical decompression for brain swelling from large supratentorial cerebral hemispheric infarction. METHODS: All patients with stroke were screened for eligibility (age 18-75 years, National Institutes of Health Stroke Scale≥18 with Item 1a<2 [responsive to minor stimulation], and CT demonstrating unilateral, complete middle cerebral artery territory infarction by specific imaging criteria). All enrolled patients were treated using a standardized medical treatment protocol. Those with both≥4 mm of pineal shift and deterioration in level of arousal or ≥7.5 mm of anteroseptal shift within 96 hours of stroke onset were randomized to continued medical treatment only or medical treatment plus surgery. Death at 21 days was the primary outcome measure. RESULTS: Among 4909 screened patients, only 66 (1.3%) patients were eligible for HeADDFIRST. Forty patients were enrolled, and 26 patients developed the requisite brain swelling for randomization. All who failed to meet randomization criteria were alive at 21 days. Mortality at 21 and 180 days was 40% (4/10) in the medical treatment only and 21% (3/14) and 36% (5/14) in the medical treatment plus surgery arms, respectively. CONCLUSIONS: HeADDFIRST randomization criteria effectively distinguished low from high risk of death from large supratentorial cerebral hemispheric infarction. Lower mortality in the medical treatment only group than in other published trials suggests a possible benefit to standardizing medical management. These results can inform the interpretation of recently completed European trials concerning patient selection and medical management. CLINICAL TRIAL REGISTRATION: This trial was not registered because enrollment began before July 1, 2005.
Authors: Katayoun Vahedi; Jeannette Hofmeijer; Eric Juettler; Eric Vicaut; Bernard George; Ale Algra; G Johan Amelink; Peter Schmiedeck; Stefan Schwab; Peter M Rothwell; Marie-Germaine Bousser; H Bart van der Worp; Werner Hacke Journal: Lancet Neurol Date: 2007-03 Impact factor: 44.182
Authors: Jeannette Hofmeijer; L Jaap Kappelle; Ale Algra; G Johan Amelink; Jan van Gijn; H Bart van der Worp Journal: Lancet Neurol Date: 2009-03-05 Impact factor: 44.182
Authors: R von Kummer; U Meyding-Lamadé; M Forsting; L Rosin; K Rieke; W Hacke; K Sartor Journal: AJNR Am J Neuroradiol Date: 1994-01 Impact factor: 3.825
Authors: Eric Jüttler; Stefan Schwab; Peter Schmiedek; Andreas Unterberg; Michael Hennerici; Johannes Woitzik; Steffen Witte; Ekkehart Jenetzky; Werner Hacke Journal: Stroke Date: 2007-08-09 Impact factor: 7.914
Authors: J Bösel; S Schönenberger; C Dohmen; E Jüttler; D Staykov; K Zweckberger; W Hacke; S Schwab; M T Torbey; H B Huttner Journal: Nervenarzt Date: 2015-08 Impact factor: 1.214
Authors: Hormuzdiyar H Dasenbrock; Faith C Robertson; M Ali Aziz-Sultan; Donovan Guittieres; Rose Du; Ian F Dunn; William B Gormley Journal: Neurocrit Care Date: 2016-12 Impact factor: 3.210
Authors: W Taylor Kimberly; Matthew B Bevers; Rüdiger von Kummer; Andrew M Demchuk; Javier M Romero; Jordan J Elm; Holly E Hinson; Bradley J Molyneaux; J Marc Simard; Kevin N Sheth Journal: Neurology Date: 2018-11-16 Impact factor: 9.910
Authors: Chesney S Oravec; Christine Tschoe; Kyle M Fargen; Carol A Kittel; Alejandro Spiotta; Eyad Almallouhi; Robert M Starke; David J McCarthy; Scott Simon; Stephanie Zyck; Grahame C Gould; Reade De Leacy; J Mocco; Adnan Siddiqui; Sasha Vaziri; W Christopher Fox; Justin F Fraser; Rohan Chitale; Gregory Zipfel; Anna Huguenard; Stacey Q Wolfe Journal: Neuroradiol J Date: 2021-07-16